Volume 87, Issue 1, Pages 200-209 (January 2015) Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease  Holger Reinecke, Michael Nabauer, Andrea Gerth, Tobias Limbourg, Andras Treszl, Christiane Engelbertz, Lars Eckardt, Paulus Kirchhof, Karl Wegscheider, Ursula Ravens, Thomas Meinertz, Gerhard Steinbeck, Günter Breithardt  Kidney International  Volume 87, Issue 1, Pages 200-209 (January 2015) DOI: 10.1038/ki.2014.195 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 Proportion of patients with distinct CHADS2 (Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke) score depending on their renal function. The CHADS2 scores were significantly different between the chronic kidney disease (CKD) stages. The dotted line outlines the CHADS2 scores of <2 from CHADS2 scores of ≥2. Detailed data are found in Table 2 Kidney International 2015 87, 200-209DOI: (10.1038/ki.2014.195) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 2 Treatment differences according to chronic kidney disease (CKD) stages. (a) In-hospital treatment and CKD stages. Although the proportion of patients receiving pharmacological conversion, electrical cardioversion, and catheter ablation was lower with advanced CKD, the frequency of pacemaker implantation and cardiovascular surgery during index treatment increased significantly with worse renal function. (b) In-hospital drug treatment and CKD stage. Chronic therapy with class I (flecainide) and class III (sotalol) antiarrhythmic drugs decreased significantly with decreasing renal function, whereas prescription rates for amiodarone increased with decreasing renal function. No difference could be observed for β-blocker or oral anticoagulation therapy. Kidney International 2015 87, 200-209DOI: (10.1038/ki.2014.195) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Multivariate analysis of treatment options according to estimated glomerular filtration rate (eGFR) per 10 ml/min per 1.73 m2 decrease. Data were adjusted for age, female gender, arterial hypertension, diabetes, nonsmoking, previous myocardial infarction (MI), valvular heart disease, major cause for index presentation, CHADS2 (Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke) score, all thromboembolic complications, and significant hemorrhage. OR, odds ratio; LCL, lower confidence limit; UCL, upper confidence limit. Kidney International 2015 87, 200-209DOI: (10.1038/ki.2014.195) Copyright © 2015 International Society of Nephrology Terms and Conditions